No Data
No Data
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab
Hong Kong's Department of Health has approved a new drug application for Shanghai Junshi Biosciences' (SHA:688180, HKG:1877) cancer drug toripalimab, according to a Wednesday release filed with the Ho
Hong Kong stock changes丨Junshi Biotech rose more than 5%, and the application for marketing license of treprilizumab was accepted by DO
Gelonghui, April 25 | Junshi Biotech (1877.HK) rallied more than 5% and now reports HK$10.22, with a total market value of HK$10 billion. Junshi Biotech's A shares are currently up 4% to 25.79 yuan. According to the news, the company received a notice from the Drug Administration (DO) of the Hong Kong Department of Health that treprimab (product code: TAB001/JS001) combined with cisplatin/gemcitabine is used as first-line treatment for adult patients with metastatic or recurrent locally advanced nasopharyngeal cancer, and as a single agent for recurrent, unresectable, or metastatic nasopharyngeal cancer patients whose disease progresses during or after treatment containing platinum
Changes in Hong Kong stocks | Innovative drug concept stocks rose higher, Keji Pharmaceutical-B (02171) rose more than 11%, and innovative drugs ushered in a full-process support mechanism
Innovative drug concept stocks continued to rise. As of press release, Keji Pharmaceutical-B (02171) rose 10.3% to HK$5.57; Laikai Pharmaceutical-B (02105) rose 9.15% to HK$6.44; and Rongchang Biotech (09995) rose 6.29% to HK$31.25.
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the
Junshi Biotech (01877) appoints Wang Zhengyu as board secretary
Zhitong Finance App News, Junshi Biotech (01877) issued an announcement. Due to career development reasons, Chen Yingge applied to resign as secretary of the company's board of directors, joint company secretary and authorized representative. The resignation took effect from the date it was delivered to the company's board of directors. After Chen Yingge's resignation, he will no longer hold any position in the company. Furthermore, after the qualification review of the nomination committee of the 3rd board of directors of the company, the company held the 30th meeting of the 3rd board of directors on April 24, 2024 to review and pass the “Proposal on Appointing the Company's Board Secretary, Joint Company Secretary and Authorized Representative”. The details are as follows: Wang Zhengyu was appointed as the secretary of the company's board of directors
Express News | Junshi Biotech: Application for marketing license of treprilizumab was accepted by the Drug Office of the Hong Kong Department of Health
No Data